#AIOM23 Massimo Di Maio, next president elect “The person I would like to be in 10 years”, as Matteo Lambertini, MD PhD said this morning👏🏼 AIOM

#mentorship is a mutual relationship. So proud of you Sergio Facchini

Patient preference for place of death is unique to their individual circumstances & belief systems 👉faith, symptom burden, social support, socioeconomic status, & geography may affect the delivery of quality #endoflife care. #OvarianCancer #gyncsm #hpm 📍journals.lww.com/greenjournal/f…

What just happened? 5 new 💊/indications ✅ by FDA Oncology in the last 10 days. As #CommunityOncologists, we need to know them all: 1.#Fruquintinib in refractory mCRC, mPFS 3.7mos vs 1.8mos 2.#Pembrolizumab (+Chemo) in 1L mGEJ/Gastric Ca, mOS 12.9mos Vs 11.5mos

👏🏼Congrats to Pashtoon Kasi MD, MS and team for their latest work, part of our research topic exploring🩸 liquid biopsy in CRC 🗣️ frontiersin.org/research-topic… Frontiers - Oncology Alfonso De Stefano Sergio Facchini 👇🏼

👏🏼Kudos to Daniele Rossini Chiara Cremolini and team for their latest work, part of our research topic exploring🩸 #liquidbiopsy in #CRC 🗣️ frontiersin.org/research-topic… Frontiers - Oncology Alfonso De Stefano Sergio Facchini 👇🏼 preliminary data from the ph 2 #PARERE trial frontiersin.org/articles/10.33…

The first piece of knowledge from PARERE trial by GONO Foundation ✅ > 200 pts candidate to antiEGFR rechallenge screened with #liquidbiopsy 🩸 ⛔️38% RAS or BRAF mutations in ctDNA 🔢 30% RAS/BRAF wt cases with at least one potential mechanism of resistance Paolo Ciracì

È con grande orgoglio e soddisfazione che vi comunichiamo l'approvazione al Senato della Repubblica della Legge per il #dirittoallobliooncologico. È stato premiato l’impegno di tutti quelli che hanno creduto in questa legge di civiltà che abbiamo affrontato con Fondazione Aiom.

What a journey ! Grateful to ESMO - Eur. Oncology& the #ESMOYOC family across the last years

So proud of Jon Lim, MRCP PhD Shining at #AACR24

The #PrecisionOncology webinar presents ESMO’s new proposal for a classification of tissue-agnostic therapeutics. Register now for free and take part in this live interaction with international experts.

🚨Curious about #Tumour #agnostic treatments? Don't miss out! Join us tomorrow for an illuminating #PrecisionOncology webinar featuring international experts. 👉There's still time to register. See you there! 🌟 ESMO - Eur. Oncology Annals of Oncology Register now with your ESMO account:

👉The last webinar in the #PrecisionOncology series is now available to the entire oncology community. Access with your ESMO account: 🔗ow.ly/QbL750Rj8oz Claudia Cardone Vivek Subbiah, MD Sewanti Limaye 🇮🇳🇺🇸 Ben Westphalen George Pentheroudakis

“Alle bambine ribelli di tutto il mondo: sognate più in grande, puntate più in alto, lottate con più energia. E, nel dubbio, ricordate: avete ragione voi!” Quale altro meeting in sanità dà spazio a parole come queste? ♥️ Francesca Cavallo

📢 Very happy to share our latest paper Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis, just published in Cancer Discovery Explore our findings here: aacrjournals.org/cancerdiscover… 🩸🧬💻

Matteo Lambertini, MD PhD is leading the most innovative research efforts to provide clear data about fertility preservation techniques and clinical outcomes in women with cancer. Sadly, this topic is still a taboo. As a woman and as oncologist, I feel so grateful. Keep shining, Matte!

Present and future of immunotherapy? #Bridge2024 in Napoli, not to be missed Paolo A. Ascierto